🇪🇺 Invokana Pill in European Union

EMA authorised Invokana Pill on 23 April 2014

Marketing authorisation

Application: EMEA/H/C/002656
Marketing authorisation holder: Janssen-Cilag International NV
Local brand name: Vokanamet
Indication: Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients not adequately controlled on their maximally tolerated doses of metformin alone in patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control. in patients already being treated with the combination of canagliflozin and metformin as separate tablets For study results with respect to combination of therapies, ef
Status: approved

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Is Invokana Pill approved in European Union?

Yes. EMA authorised it on 23 April 2014.

Who is the marketing authorisation holder for Invokana Pill in European Union?

Janssen-Cilag International NV holds the EU marketing authorisation.